• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Clinical efficacy of montelukast sodium combined with budesonide or combined with loratadine in treating children with cough variant asthma and influence on inflammatory factors in the serum
【2h】

Clinical efficacy of montelukast sodium combined with budesonide or combined with loratadine in treating children with cough variant asthma and influence on inflammatory factors in the serum

机译：孟鲁司特钠联合布地奈德或氯雷他定治疗儿童咳嗽变异性哮喘及其对血清炎症因子的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Clinical efficacy of montelukast sodium combined with budesonide or combined with loratadine in children with cough variant asthma was investigated. A retrospective analysis of the medical records of 72 children with cough variant asthma who were treated in Xuzhou Children's Hospital, Xuzhou Medical University from April 2015 to August 2017 was performed and the 72 child patients were divided into two groups: 35 children were treated with montelukast sodium combined with budesonide in Group A, and 37 children were treated with montelukast sodium combined with loratadine in Group B. The clinical efficacy of the two groups was evaluated according to the lung function indexes [forced expiratory volume in the first second (FEV1), ratio of the forced expiratory volume in the first second to the forced vital capacity (FEV1/FVC), the peak expiratory flow (PEF)], the inflammation biomarkers [tumor necrosis factor-α (TNF-α) and interleukin-4 (IL-4)], the level of eosinophil granulocyte, and the level of IgE at three time-points: before treatment, the 4th week after treatment, and the 12th week after treatment as well as adverse reactions, recurrence of symptoms, and treatment compliance were recorded. After treatment, the levels of FEV1, FEV1/FVC, PEF, TNF-α and IL-4, eosinophil granulocyte and IgE in the two groups were significantly improved (P<0.05). The treatment compliance of Group A was significantly lower than that of Group B (P<0.05). In conclusion, the method of montelukast sodium combined with budesonide or loratadine are both worthy of clinical promotion because they have equivalent efficacy in the treatment of cough variant asthma to effectively improve the lung function and inflammatory response in patients and both bring less adverse reactions and lower recurrence rate.
机译：研究了孟鲁司特钠联合布地奈德或氯雷他定对儿童咳嗽变异性哮喘的临床疗效。回顾性分析2015年4月至2017年8月在徐州医科大学徐州儿童医院接受治疗的72例咳嗽变异性哮喘患儿的病历，将72例患儿分为两组：35例接受孟鲁司特治疗钠联合布地奈德治疗，A组37例，孟鲁司特钠联合氯雷他定治疗B组。根据肺功能指标评估两组的临床疗效[第一秒钟强迫呼气量（FEV1），第一秒钟的强制呼气量与强制肺活量（FEV1 / FVC）的比值，呼气峰流量（PEF）]，炎症生物标志物[肿瘤坏死因子-α（TNF-α）和白介素4（IL -4）]，三个时间点的嗜酸性粒细胞水平和IgE水平：治疗前，治疗后第4周和治疗后第12周以及不良反应，记录症状的出现和治疗依从性。治疗后，两组FEV1，FEV1 / FVC，PEF，TNF-α，IL-4，嗜酸性粒细胞和IgE水平明显升高（P <0.05）。 A组的治疗依从性明显低于B组（P <0.05）。总之，孟鲁司特钠联合布地奈德或氯雷他定的方法均值得临床推广，因为它们在治疗咳嗽变异性哮喘方面具有同等效力，可有效改善患者的肺功能和炎症反应，并且不良反应少且降低。复发率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号